Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

654 - Novel cKIT kinase inhibitor, BPRCKJ001, as an advanced therapeutic candidate for GIST


17 Dec 2016


Poster lunch


Hui-Yi Shiao


Annals of Oncology (2016) 27 (suppl_9): ix1-ix8. 10.1093/annonc/mdw573


H. Shiao1, H. Tsai2, W. Lin1, T. Tsu1, T. Yeh1, C. Chen1, W. Jiaang1

Author affiliations

  • 1 Institute Of Biotechnology And Pharmaceutical Research, National Health Research Institutes, 350 - Miaoli County/TW
  • 2 National Institute Of Cancer Research, National Health Research Institutes, 350 - Miaoli County/TW


Abstract 654


During the past decade, first-line use of imatinib has benefited GIST patients. GIST patients develop imatinib-resistance due to secondary mutation in cKIT after 20-24 months of drug treatment. Although the 2nd line drugs such as, sunitinib is effective, activation loop mutations quickly overcame their potent inhibitory effects. Moreover, these drugs have numerous potential side-effects. Even with the newly launched sorafenib and nilotinib for advanced GIST, the long term clinical outcome was still not very promising for GIST patients, due to the rapid development of drug resistance on cKIT.


IBPR has identified a series of novel cKIT inhibitors, the BPRCKJ series, which exhibited potent cKIT kinase activity inhibition. To evaluate the potential of BPRCKJ compounds as novel cKIT inhibitors against GIST, eight different imatinib-resistant mutated cKITs were selected to examine the inhibitory activities of BPRCKJ series. The results showed that BPRCKJ series has a broad spectrum activity against various forms of imatinib-resistant mutant c-KITs. Most importantly, the ability to overcome imatinib- and sunitinib-resistant mutant cKITs is demonstrated.


Through the comprehensive SAR study, we had identified BPRCKJ001 as a potential candidate, which was shown to strongly inhibit the enzymatic activities of several mutant c-KIT. BPRCKJ001 also effectively inhibited three GIST sensitive and resistant cell lines with IC50 values below 20 nM. It is interesting to note that BPRCKJ001 is 10-times and 400-times more potent than sunitinib in GIST430 cells and sunitinib-resistant cell lines (GIST48), respectively. The Western blot analyses also clearly showed that BPRCKJ001 can suppress the cKIT phosphorylation and downstream AKT phosphorylation more effectively than imatinib and sunitinib in GIST430 cells.


BPRCKJ001 had shown excellent in vitro effects, targeting against both imatinib- and sunitinib-resistant mutants in both enzymatic and cellular systems. More importantly, BPRCKJ001 also demonstrated in vivo efficacy by oral administration in GIST430 xenograft model. These results indicate that CKJBPR001 series has reasonable pharmaceutical properties to be developed as a potential cKIT inhibitor

Clinical trial indentification

Legal entity responsible for the study

Weir-Torn Jiaang


MOEA, Taiwan


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings